These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 1752534)

  • 1. [Essential thrombocythemia: conventional therapy].
    Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
    Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract]   [Full Text] [Related]  

  • 2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary thrombocythemia: new drugs for an evolving disease.
    Balduini CL
    Haematologica; 1992; 77(4):297-301. PubMed ID: 1427439
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Solberg LA
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary thrombocythemia.
    Jamshidi K; Ansari A; Windschitl HE; Swaim WR
    Geriatrics; 1973 Jan; 28(1):121-33. PubMed ID: 4539498
    [No Abstract]   [Full Text] [Related]  

  • 7. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).
    Brodsky I
    Am J Clin Oncol; 1998 Feb; 21(1):105-6. PubMed ID: 9499248
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
    Elliott MA; Tefferi A
    Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
    Randi ML; Fabris F; Girolami A
    Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Dingli D; Tefferi A
    Curr Hematol Malig Rep; 2006 Jun; 1(2):69-74. PubMed ID: 20425334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
    Sever M; Newberry KJ; Verstovsek S
    Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of elderly patients with myeloproliferative disorders.
    Tura S
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract]   [Full Text] [Related]  

  • 16. Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report.
    Murphy S; Rosenthal DS; Weinfeld A; Briere J; Faguet GB; Knospe WH; Landaw SA; Laszlo J; Pisciotta AV; Tartaglia AP
    Cancer Treat Rep; 1982 Jul; 66(7):1495-500. PubMed ID: 7046930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients.
    Chistolini A; Mazzucconi MG; Ferrari A; la Verde G; Ferrazza G; Dragoni F; Vitale A; Arcieri R; Mandelli F
    Haematologica; 1990; 75(6):537-40. PubMed ID: 2098295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of polycythaemia vera and essential thrombocythaemia.
    Tefferi A; Silverstein MN
    Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.